Adma Biologics Inc. (NASDAQ:ADMA) shares rose 6.4% during mid-day trading on Friday . The stock traded as high as $6.49 and last traded at $6.49, with a volume of 66,052 shares traded. The stock had previously closed at $6.10.

ADMA has been the subject of several analyst reports. Maxim Group lowered their target price on Adma Biologics from $24.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, July 25th. Raymond James Financial Inc. lowered Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research report on Monday, August 1st.

The firm has a 50-day moving average of $6.60 and a 200-day moving average of $6.40. The firm’s market capitalization is $83.63 million.

Adma Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.11. On average, equities research analysts predict that Adma Biologics Inc. will post ($1.49) earnings per share for the current year.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.